377 related articles for article (PubMed ID: 26614902)
1. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
2. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
3. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
5. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
6. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
7. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
8. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
9. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
10. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Karlin L; Robak T; Gladstone DE; le Coutre P; Dietrich S; Gotic M; Larratt L; Offner F; Schiller G; Swords R; Bacon L; Bocchia M; Bouabdallah K; Breems DA; Cortelezzi A; Dinner S; Doubek M; Gjertsen BT; Gobbi M; Hellmann A; Lepretre S; Maloisel F; Ravandi F; Rousselot P; Rummel M; Siddiqi T; Tadmor T; Troussard X; Yi CA; Saglio G; Roboz GJ; Balic K; Standifer N; He P; Marshall S; Wilson W; Pastan I; Yao NS; Giles F
Leukemia; 2018 Aug; 32(8):1768-1777. PubMed ID: 30030507
[TBL] [Abstract][Full Text] [Related]
11. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
12. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
Lin AY; Dinner SN
Blood Adv; 2019 Oct; 3(19):2905-2910. PubMed ID: 31594764
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; FitzGerald DJ; Santiago L; Gao G; Lanasa MC; Pastan I
Blood; 2018 May; 131(21):2331-2334. PubMed ID: 29487070
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; Fitzgerald DJ; Lechleider R; Pastan I
J Clin Oncol; 2012 May; 30(15):1822-8. PubMed ID: 22355053
[TBL] [Abstract][Full Text] [Related]
15. Immunobiological treatments of hairy-cell leukaemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2003 Mar; 16(1):117-33. PubMed ID: 12670470
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia-new genes, new targets.
Kreitman RJ
Curr Hematol Malig Rep; 2013 Sep; 8(3):184-95. PubMed ID: 23892906
[TBL] [Abstract][Full Text] [Related]
18. Approach to the patient after relapse of hairy cell leukemia.
Kreitman RJ; Fitzgerald DJ; Pastan I
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
[TBL] [Abstract][Full Text] [Related]
19. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Kang C
Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
[TBL] [Abstract][Full Text] [Related]
20. [Moxetumomab pasudotox-Third line in Hairy cell leukemia].
Montes L; Herbaux C
Bull Cancer; 2021 Dec; 108(12):1073-1074. PubMed ID: 34776118
[No Abstract] [Full Text] [Related]
[Next] [New Search]